报价延迟最少15分钟:2026/01/09 09:59 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.2502 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-11.91/--
|
|
企业价值
4.81M
|
| 资产负债 |
|
每股账面净值
4.46
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
901
|
|
每股收益
0.00
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluatedby these tests to the drivers of coronary heart disease. |
